Indaptus Therapeutics INDP Stock Is It a Good Entry Point Indaptus Therapeutics misses EPS views no revenue US Institutional and Governance Risk Assessment 2026 VDem Democracy Report Analysis APAM Artisan notches 139 percent Q4 2025 EPS beat but shares drop 089 percent in daily trading Lam Research Corporation LRCX MATCH Act Policy Scrutiny Highlights China Exposure Risks Amid Contrasting Valuation and NearTerm Momentum Global AI Sector Disruption and US Market Reaction Following DeepSeek R1 Launch